Figures & data
Figure 1. Cumulative distribution functions of the number of monovalent oral poliovirus vaccine (mOPV) doses of each serotype used in 1,000 iterations of a global model for long-term poliovirus risk management with base case assumptions for outbreak probabilities and outbreak response [Citation36,Citation53]
![Figure 1. Cumulative distribution functions of the number of monovalent oral poliovirus vaccine (mOPV) doses of each serotype used in 1,000 iterations of a global model for long-term poliovirus risk management with base case assumptions for outbreak probabilities and outbreak response [Citation36,Citation53]](/cms/asset/8fcb02fe-29be-44d5-88f3-78dab49b02aa/ierv_a_1322514_f0001_oc.jpg)
Figure 2. (a) Relationship between the number of desired finished doses, the total stockpile size, and the probability of a stock-out for serotype 1 monovalent oral poliovirus vaccine, based on the 1,000 iterations depicted in , a finishing time of 5 months, and an effective shelf-life of 18 months. (b) Lowest attainable stock-out probability by the number of desired finished doses and corresponding minimum total stockpile size
![Figure 2. (a) Relationship between the number of desired finished doses, the total stockpile size, and the probability of a stock-out for serotype 1 monovalent oral poliovirus vaccine, based on the 1,000 iterations depicted in Figure 1, a finishing time of 5 months, and an effective shelf-life of 18 months. (b) Lowest attainable stock-out probability by the number of desired finished doses and corresponding minimum total stockpile size](/cms/asset/0703feb5-ec90-4356-a7b8-07a320a1a777/ierv_a_1322514_f0002_oc.jpg)
Figure 3. Relationship between the stockpile size and lowest attainable probability of a stock-out based on the 1,000 iterations depicted in , for different assumptions. (a) Results by monovalent oral poliovirus vaccine (mOPV) serotype, with a finishing time of 5 months and a shelf life of 18 months (b) Results for serotype 1 mOPV by finishing time, with a shelf life of 18 months (c) Results for serotype 1 mOPV by shelf-life and as a function of the number of desired finished doses, with a finishing time of 5 months (d) Results for serotype 1 mOPV by shelf-life and as a function of total stockpile size, with a finishing time of 5 months
![Figure 3. Relationship between the stockpile size and lowest attainable probability of a stock-out based on the 1,000 iterations depicted in Figure 1, for different assumptions. (a) Results by monovalent oral poliovirus vaccine (mOPV) serotype, with a finishing time of 5 months and a shelf life of 18 months (b) Results for serotype 1 mOPV by finishing time, with a shelf life of 18 months (c) Results for serotype 1 mOPV by shelf-life and as a function of the number of desired finished doses, with a finishing time of 5 months (d) Results for serotype 1 mOPV by shelf-life and as a function of total stockpile size, with a finishing time of 5 months](/cms/asset/6e000272-dfaa-446d-954e-c0fcee6a34da/ierv_a_1322514_f0003_oc.jpg)
Table 1. Optimal stockpile composition for each monovalent oral poliovirus vaccine (mOPV) serotype for different stock-out probabilities, assuming a finishing time of 5 months and an effective shelf life of 18 months, based on 1000 iterations of a global model [Citation36,Citation53]